NFE2L2 and non-small cell lung carcinoma: Given that NRF2 is a transcription factor for FSP1 [46], we examined whether inhibiting NRF2 would have the same effect as targeting FSP1 directly in enhancing ferroptosis in NSCLC with KEAP1 mutation.